Загрузка...
Efficacy and Safety of Alemtuzumab in Multiple Sclerosis and Impact on Nursing Role
Alemtuzumab, a humanized monoclonal antibody, has shown efficacy for relapsing-remitting multiple sclerosis (MS) in phase 2 and phase 3 trials. Compared with subcutaneous interferon beta-1a, alemtuzumab significantly reduced the risk for accumulation of disability and the rate of relapse, and improv...
Сохранить в:
| Главные авторы: | , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
The Consortium of Multiple Sclerosis Centers
2013
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3883016/ https://ncbi.nlm.nih.gov/pubmed/24453779 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7224/1537-2073.2013-004 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|